Department of Genetics, Yale School of Medicine, 295 Congress Avenue, New Haven, CT 06510, United States.
Department of Cell Biology, Yale School of Medicine, 10 Amistad Street, New Haven, CT 06510, United States.
Hum Mol Genet. 2024 Jan 7;33(2):138-149. doi: 10.1093/hmg/ddad170.
Spinocerebellar ataxia type 1 is caused by an expansion of the polyglutamine tract in ATAXIN-1. Ataxin-1 is broadly expressed throughout the brain and is involved in regulating gene expression. However, it is not yet known if mutant ataxin-1 can impact the regulation of alternative splicing events. We performed RNA sequencing in mouse models of spinocerebellar ataxia type 1 and identified that mutant ataxin-1 expression abnormally leads to diverse splicing events in the mouse cerebellum of spinocerebellar ataxia type 1. We found that the diverse splicing events occurred in a predominantly cell autonomous manner. A majority of the transcripts with misregulated alternative splicing events were previously unknown, thus allowing us to identify overall new biological pathways that are distinctive to those affected by differential gene expression in spinocerebellar ataxia type 1. We also provide evidence that the splicing factor Rbfox1 mediates the effect of mutant ataxin-1 on misregulated alternative splicing and that genetic manipulation of Rbfox1 expression modifies neurodegenerative phenotypes in a Drosophila model of spinocerebellar ataxia type 1 in vivo. Together, this study provides novel molecular mechanistic insight into the pathogenesis of spinocerebellar ataxia type 1 and identifies potential therapeutic strategies for spinocerebellar ataxia type 1.
脊髓小脑共济失调 1 型是由 ATAXIN-1 中多聚谷氨酰胺区的扩展引起的。Ataxin-1 在大脑中广泛表达,参与调节基因表达。然而,目前尚不清楚突变型 ataxin-1 是否会影响可变剪接事件的调节。我们在脊髓小脑共济失调 1 型的小鼠模型中进行了 RNA 测序,发现突变型 ataxin-1 的表达异常导致脊髓小脑共济失调 1 型小鼠小脑中多种剪接事件。我们发现,多样化的剪接事件主要以细胞自主性方式发生。大多数具有异常调节可变剪接事件的转录本以前是未知的,因此允许我们确定整体新的生物学途径,这些途径与脊髓小脑共济失调 1 型中差异基因表达所影响的途径不同。我们还提供证据表明剪接因子 Rbfox1 介导突变型 ataxin-1 对异常调节的可变剪接的影响,并且 Rbfox1 表达的遗传操作修饰了体内脊髓小脑共济失调 1 型的果蝇模型中的神经退行性表型。总之,这项研究为脊髓小脑共济失调 1 型的发病机制提供了新的分子机制见解,并确定了脊髓小脑共济失调 1 型的潜在治疗策略。